HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Shanghai Songjiang biomedicine

Songjiang’s biomedicine firms span research, process scale-up, production and commercial services. Analysis must separate programmes in development, approved products and production lots ready for dependable delivery; clinical or registration progress is not sales volume.

Formation and regional foundations

Songjiang’s development zone expanded biomedicine space through major projects and specialised parks, while the G60 corridor connected research, capital-market disclosure and regional collaboration. Recent published projects focus on biological products, ophthalmic materials, testing services and facility upgrades.

Songjiang hosts biological medicines, ophthalmic materials, analytical work and production services. A practical review first separates research, registration, approval and routine manufacture, then follows cell-bank or material lots, analytical methods, process revisions and cold-chain records.

Core geography: Centred on biopharmaceutical, medical-device, research-service and controlled cold-chain nodes in Songjiang’s development zone, the G60 innovation corridor and Chedun, the boundary cross-checks entities against medicine and device licences and listed-company disclosures.

Songjiang biomedicine order path

Six nodes for understanding biological medicines, ophthalmic biomaterials and research-production services

Every handover carries product revision, sample or lot identity, method status and owner. A cold-chain arrow marks transfer of temperature responsibility, not regulatory approval or a sale.

  • Target and product definition — Songjiang biomedicine records the responsible party, input revision and release condition at “Target and product definition”.
  • Research and analytical methods — Songjiang biomedicine records the responsible party, input revision and release condition at “Research and analytical methods”.
  • Process scale-up and validation — Songjiang biomedicine records the responsible party, input revision and release condition at “Process scale-up and validation”.
  • Controlled production — Songjiang biomedicine records the responsible party, input revision and release condition at “Controlled production”.
  • Release and cold-chain delivery — Songjiang biomedicine records the responsible party, input revision and release condition at “Release and cold-chain delivery”.
  • Post-market quality feedback — Songjiang biomedicine records the responsible party, input revision and release condition at “Post-market quality feedback”.

01 · Songjiang biomedicine: Define the buying question first

Chapter 1 takes its checks from Target and product definition.

A biomedicine brief starts with target, indication, dosage form, development stage and expected deliverable. A sample in method development cannot be priced or accepted as a commercial medicine lot.

In decision 1, when Songjiang biomedicine moves from “Target and product definition” to “Research and analytical methods”, version, lot and change records are easiest to lose. Decision 1 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

A district plan shows hosting direction but not a candidate’s marketing authorisation or ready process. The holder, contractor and actual manufacturing address are checked directly.

02 · Songjiang biomedicine: Inputs and starting conditions

Chapter 2 takes its checks from Research and analytical methods.

Cell banks, media, excipients and ophthalmic-material inputs enter with supplier, lot, test status and storage condition. Identical material names do not establish interchangeability across grades or change histories.

In decision 2, when Songjiang biomedicine moves from “Research and analytical methods” to “Process scale-up and validation”, version, lot and change records are easiest to lose. Decision 2 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

Input release also needs sampling plan, test method and retest period; an approved-supplier list is only an entry point. Frozen or light-sensitive material cannot rely on appearance after traceability breaks.

03 · Songjiang biomedicine: How the core process connects

Chapter 3 takes its checks from Process scale-up and validation.

Scale-up changes mixing, mass transfer, filter area and hold time. Validation lots define the operating range rather than projecting a successful laboratory run directly to a large vessel.

In decision 3, when Songjiang biomedicine moves from “Process scale-up and validation” to “Controlled production”, version, lot and change records are easiest to lose. Decision 3 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

Process qualification covers worst-case load, longest hold and critical equipment differences and retains failed lots. Showing only the best batch conceals scale-up variability.

04 · Songjiang biomedicine: Where quality evidence sits

Chapter 4 takes its checks from Controlled production.

Controlled manufacture joins equipment state, environmental monitoring, critical parameters, deviations and in-process controls in one batch record. A passing final test alone cannot explain process control.

In decision 4, when Songjiang biomedicine moves from “Controlled production” to “Release and cold-chain delivery”, version, lot and change records are easiest to lose. Decision 4 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

Cleanroom grade, equipment cleaning and material hold time are checked against product risk; shared lines add residue and cross-contamination assessment. Floor area cannot replace that evidence.

05 · Songjiang biomedicine: How to compare suppliers

Chapter 5 takes its checks from Release and cold-chain delivery.

Release comparison resolves to a product and lot, with specifications, method revision, stability support, package system and temperature needs. A research platform does not give every product the same lead time.

In decision 5, when Songjiang biomedicine moves from “Release and cold-chain delivery” to “Post-market quality feedback”, version, lot and change records are easiest to lose. Decision 5 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

A temperature handover records pack-out, logger identity, dispatch and receipt times and excursion action. Carrier qualification does not replace the temperature trace for this shipment.

06 · Songjiang biomedicine: Geography and delivery radius

Chapter 6 takes its checks from Post-market quality feedback.

Research, testing and production nodes in Songjiang can collaborate, yet quality systems and legal responsibility do not merge when samples, bulk or finished goods move. Distance is assessed with the permitted transit time.

In decision 6, when Songjiang biomedicine moves from “Post-market quality feedback” to “Target and product definition”, version, lot and change records are easiest to lose. Decision 6 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

Cross-site testing adds sample custody, method transfer and result-approval authority. Calling several Songjiang legal entities one base obscures who owns release responsibility.

07 · Songjiang biomedicine: Resource efficiency and compliance

Chapter 7 takes its checks from Target and product definition.

Yield, right-first-time rate, water use and liquid waste need a product, scale and period. Biosafety, emissions and medicine quality follow different regimes and are not replaced by a green-factory label.

In decision 7, when Songjiang biomedicine moves from “Target and product definition” to “Research and analytical methods”, version, lot and change records are easiest to lose. Decision 7 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

Inspections, licences and projects are dated, and a newer record does not automatically cover another site or product. Compliance keeps scope and separates open actions from closed ones.

08 · Songjiang biomedicine: Turn diligence into a decision

Chapter 8 takes its checks from Research and analytical methods.

The final decision joins product status, site, process revision, methods, quality agreement and change notification in one list. A representative lot should test deviation, excursion and recall handovers before expansion.

In decision 8, when Songjiang biomedicine moves from “Research and analytical methods” to “Process scale-up and validation”, version, lot and change records are easiest to lose. Decision 8 links inputs, process parameters and release results to show whether batch records, analytical methods, release specifications and temperature traceability are genuinely controlled.

A pre-contract lot uses the real package, route and receiving laboratory rather than demonstration data. The agreement also sets sample retention, investigation timing and lot-disposition authority.

Sources and reading notes

District material establishes the Songjiang industry setting, while project and company originals support only their stated research, facility or product status. Clinical progress, registration events, design capacity, production lots and sales retain their own dates and subjects.

  • Published material confirms the boundary and main carrying spaces of Songjiang biomedicine, but district-wide totals cannot be assigned to one company.
  • Biological medicines, ophthalmic biomaterials and analytical services use different approvals, methods and deliverables and cannot share one capacity figure.
  • A programme in development, an approved product and a released commercial lot are three different states. Inclusion also does not place every capability at one Songjiang site.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • Huadao (Shanghai) Biopharma Co Ltd — Huadao (Shanghai) Biopharma Co Ltd contributes Cell-technology research, process transfer and quality-research services within Songjiang biomedicine. Public sources establish the entity and product direction for Huadao (Shanghai) Biopharma Co Ltd, while specifications, capacity, price and lead time remain order-specific.
  • Shanghai Haohai Biological Technology Co Ltd — Shanghai Haohai Biological Technology Co Ltd contributes Development and manufacture of ophthalmic and medical biomaterials within Songjiang biomedicine. Public sources establish the entity and product direction for Shanghai Haohai Biological Technology Co Ltd, while specifications, capacity, price and lead time remain order-specific.
  • Shanghai Henlius Biopharmaceutical Co Ltd — Shanghai Henlius Biopharmaceutical Co Ltd contributes Research, production and quality management for biological medicines within Songjiang biomedicine. Public sources establish the entity and product direction for Shanghai Henlius Biopharmaceutical Co Ltd, while specifications, capacity, price and lead time remain order-specific.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.